GABBR1 and Gaucher disease: Using the clinical, genetic, and biochemical data from the 160 newly diagnosed treatment-naïve GD patients from the “Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease” (LYSO-PROOF) study, we aimed to investigate the application of lyso-Gb1 as a predictive biomarker for the clinical severity of the patients’ genotype.